Coherus Nears FDA Filing Date For Humira Biosimilar

R&D Spend Ramps Up Ahead Of Planned 2023 Launch

 
• By Dean Rudge
  
SiliconValley
California-based Coherus plans to file its CHS-1420 adalimumab asset during Q4 • Source: Shutterstock

More from Biosimilars

More from Products